Chimeric Therapeutics Limited (CHMMF)
Market Closed
10 Aug, 20:00
OTC PINK OTC PINK Primary $
0. 10
0
0%
$
4.1M Market Cap
- P/E Ratio
- Div Yield
30,000 Volume
0 Eps
$ 0.1
Previous Close Want to track CHMMF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CHMMF closed yesterday higher at $0.1, an increase of 0% from Friday's close, completing a monthly increase of 0% or $0. Over the past 12 months, CHMMF stock gained 9,900%.
CHMMF is not paying dividends to its shareholders.
The last earnings report, released on Feb 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Chimeric Therapeutics Limited has completed 1 stock splits, with the recent split occurring on Apr 22, 2026.
The company's stock is traded on one exchange.
Chimeric Therapeutics Limited (CHMMF) FAQ
What is the stock price today?
The current price is $0.10.
On which exchange is it traded?
Chimeric Therapeutics Limited is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is CHMMF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 4.1M.
Has Chimeric Therapeutics Limited ever had a stock split?
Chimeric Therapeutics Limited had 1 splits and the recent split was on Apr 22, 2026.
Chimeric Therapeutics Limited Profile
| Biotechnology Industry | Healthcare Sector | Rebecca McQualter CEO | OTC PINK Exchange | AU0000121576 ISIN |
| AU Country | 5 Employees | - Last Dividend | 22 Apr 2026 Last Split | - IPO Date |
Overview
Chimeric Therapeutics Limited is a trailblazer in the field of cell therapy, focusing primarily on the development and commercialization of innovative treatments for various cancers. Established in 2020 and headquartered in Carlton, Australia, this clinical stage company is dedicated to harnessing the potential of cell therapies to fight oncology. Chimeric's approach involves advancing a portfolio of promising treatments through various stages of clinical trials, emphasizing their commitment to meeting the urgent needs of patients battling cancer.
Products and Services
Chimeric Therapeutics Limited is pioneering in several groundbreaking cell therapies targeting a range of cancers:
- CHM CDH17 CAR T cell therapy: This therapy is at the forefront of addressing advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors. It is currently undergoing Phase I/II multi-centre clinical trials, showcasing Chimeric's dedication to tackling hard-to-treat cancers with cutting-edge cell therapy technologies.
- CHM CLTX Chlorotoxin CAR T cell therapy: Specifically designed for patients with recurrent or progressive Glioblastoma, this therapy demonstrates Chimeric's innovation in targeting brain cancer. It is in phase Ia/IIb clinical trials, and also in preclinical trials for MMP2 expressing solid tumors, highlighting the potential broader applicability of the technology.
- CHM CORE-NK: Addressing both hematologic malignancies and solid tumors, this therapy is in phase Ia/IIb clinical trials for acute myeloid leukemia (AML)/colorectal cancer and acute myeloid cancer. Additionally, it is in preclinical trials for a range of cancer types, including blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The broad therapeutic range of CHM CORE-NK underscores Chimeric's commitment to expanding its impact across various cancer indications.
Contact Information
Address: 62 Lygon Street
Phone: 61 3 9824 5254
Website: https://www.chimerictherapeutics.com
